.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its own top biopharma pick for 2025 and also measured another nine labels in the room as obese. The assets banking company pointed out in a keep in mind that it continues to believe “diabesity is set to come to be.